Potential Therapeutic Effects of a GLP-1 Analogue on Blood Pressure in Morbidly Obese Patient: A Case Report

Obesity is a global pandemic associated with various cardiometabolic disorders. Several new medications are being developed for the treatment of obesity. Glucagon-like peptide-1 (GLP-1) is naturally secreted in the intestine and plays an important role in regulating insulin and glucagon secretion. It is also responsible for managing post-prandial glucose excursions and reduced appetite. Currently, GLP-1 analogues are being used for the treatment of obesity. This is a case of a morbidly obese hypertensive patient with a body mass index (BMI) of 62.84 kg/m², who was treated with a GLP-1 analogue, and experienced significant weight loss. Initially, the patient was taking three different antihypertensive medications to manage his blood pressure. As the patient’s BMI declined, the blood pressure readings also began to improve. Eventually, the patient was taken off antihypertensive medications and maintained a mean blood pressure of 113/74 mmHg at a BMI of 47.37 kg/m².